复方丹参滴丸、曲美他嗪联合治疗慢性充血性心力衰竭疗效观察

目的：研究复方丹参滴丸、曲美他嗪联合治疗慢性充血性心力衰竭的临床疗效与血清高敏C反应蛋白（hs-CRP）水平的变化情况。方法：将90例慢性充血性心力衰竭患者随机分为治疗组和对照组各45例,对照组给予ACEI类（或ARB类）、β受体阻滞药、利尿剂、洋地黄类药物等药物治疗;治疗组在上述治疗的基础上加用复方丹参滴丸10粒,tid,曲美他嗪20mg,tid,治疗8周后,作6min步行试验（6-MWT）,超声心动图监测左室射血分数（LVEF）、早期盈充速度（E）、晚期盈充速度（A）、血清hs-CRP水平,将所得的数据与治疗前作比较。结果：经治疗后两组患者心动功能均有改善,治疗组更为显著（P〈0.05）。血清hs-CRP均下降,但治疗组更为显著（P〈0.05）。结论：复方丹参滴丸、曲美他嗪联合治疗慢性充血性心力衰竭的临床疗效好,可以作为其治疗的基本药物。

Observasion on effect of compound danshen droplet-pill combine with trimetazidine in chronic congestive heart failure

Objective：To study the effect and plasma high sensitivity C-reactive protein（hs-CRP） levels change of compound danshen droplet-pill combine with trimetazidine in chronic congestive heart failure.Methods：90 patients with chronic congestive heart failure were randomly divided into treatment group and control group 45 cases,the control group were given ACEIs（or ARBs）,β-RBs,diuretics,digitalis drugs,medication,the treatment group were on the basis of the above plus,compound danshen droplet-pill 10 pills,3 times orally;trimetazidine 20 mg,3 times orally for 8 weeks.For the 6-minute walk test（6-MWT）,echocardiographic left ventricular ejection fraction（LVEF）,profit rate of early filling（E）,profit rate of late filling（A）,hs-CRP plasma levels,and compared the data collected before treatment.Results：After treatment,both the cardiac function were improved but the treatment group was more significant（P0.05）.Serum hs-CRP was decreased,but the treatment group was more significant（P0.05）.Conclusion：The clinical efficacy of compound danshen droplet-pill combine with trimetazidine in the treatment of chronic congestive heart failure is better,and it can be as the CHF essential drugs.